A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease

Exclusion Criteria

• •Life expectancy \<24 months
• •Patients who cannot receive dual antiplatelet therapy (aspirin 100mg and clopidogrel 75mg) or anticoagulation therapy
• •Patients with known allergies to: nitinol (nickel titanium); or contrast agent, that cannot be medically managed
• •Participation in another study with investigational drug/device within the 30 days preceding and during the present study
• •Previous enrolment into the current study
• •Prior stenting at the location of intended stenting
• •Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system
• •Enrolment of study investigator, his/her family members, employees and other dependent persons
• •If female and of childbearing potential: known pregnancy or a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating